



## Challenges and Future Trends of COVID-19 Vaccination

Guest Editor:

**Dr. Imran Raza Mirza**

UNICEF, New York, NY 10017, USA

Deadline for manuscript  
submissions:

**closed (31 August 2023)**

### Message from the Guest Editor

Dear Colleagues,

During 2020 and 2021, a combination of supply shortages, manufacturing challenges, intense competition for vaccines, export bans, and delays to regulatory approvals has meant that many low- and lower-middle income countries were left behind as deliveries of COVID-19 vaccines increased in higher-income countries. While some high-income countries have vaccinated more than 70% of their population, many LMICs has vaccinated less than their 10% populations so far.

We are pleased to invite you to submit your original manuscripts, reviews, position papers, and case studies which discuss implementation, surveillance, research, programs of COVID-19 vaccination, policies related to COVID-19 vaccination, and social and behavioral science strategies supporting vaccine acceptance. We especially welcome submissions exploring vaccination amongst diverse and marginalized communities that have been acutely affected by the COVID-19 pandemic. Submissions dealing with lessons learned from the past and current health crises relating to pandemic preparedness in the future will also be considered.

We look forward to receiving your contributions.

Dr. Imran Raza Mirza

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)